Literature DB >> 9925986

Transcriptional regulation and biological significance of the insulin like growth factor II gene.

W Engström1, A Shokrai, K Otte, M Granérus, A Gessbo, P Bierke, A Madej, M Sjölund, A Ward.   

Abstract

The insulin like growth factors I and II are the most ubiquitous in the mammalian embryo. Moreover they play a pivotal role in the development and growth of tumours. The bioavailability of these growth factors is regulated on a transcriptional as well as on a posttranslational level. The expression of non-signalling receptors as well as binding proteins does further tune the local concentration of IGFs. This paper aims at reviewing how the transcription of the IGF genes is regulated. The biological significance of these control mechanisms will be discussed.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9925986      PMCID： PMC6647699          DOI： 10.1111/j.1365-2184.1998.tb01196.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN： 0960-7722            Impact factor:   6.831


  169 in total

Review 1.  Insulin-like growth factors and ovarian follicular development.

Authors:  L C Giudice
Journal:  Endocr Rev       Date:  1992-11       Impact factor: 19.871

Review 2.  Insulin-like growth factor binding proteins.

Authors:  M M Rechler
Journal:  Vitam Horm       Date:  1993       Impact factor: 3.421

Review 3.  Genomic imprinting: review and relevance to human diseases.

Authors:  J G Hall
Journal:  Am J Hum Genet       Date:  1990-05       Impact factor: 11.025

4.  Insulin-like growth factor II stimulates cell proliferation through the insulin receptor.

Authors:  A Morrione; B Valentinis; S Q Xu; G Yumet; A Louvi; A Efstratiadis; R Baserga
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

5.  Genomic imprinting--defusing the ovarian time bomb.

Authors:  S Varmuza; M Mann
Journal:  Trends Genet       Date:  1994-04       Impact factor: 11.639

6.  Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice.

Authors:  K Reiss; W Cheng; A Ferber; J Kajstura; P Li; B Li; G Olivetti; C J Homcy; R Baserga; P Anversa
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

7.  Repression of promoters for the mouse insulin-like growth factor II-encoding gene (Igf-2) by products of the Wilms' tumour suppressor gene wt1.

Authors:  A Ward; J A Pooler; K Miyagawa; A Duarte; N D Hastie; A Caricasole
Journal:  Gene       Date:  1995-12-29       Impact factor: 3.688

8.  Relaxation of imprinted genes in human cancer.

Authors:  S Rainier; L A Johnson; C J Dobry; A J Ping; P E Grundy; A P Feinberg
Journal:  Nature       Date:  1993-04-22       Impact factor: 49.962

9.  The cis-acting elements involved in endonucleolytic cleavage of the 3' UTR of human IGF-II mRNAs bind a 50 kDa protein.

Authors:  W Scheper; P E Holthuizen; J S Sussenbach
Journal:  Nucleic Acids Res       Date:  1996-03-15       Impact factor: 16.971

10.  Stimulatory effects of basic fibroblast growth factor on DNA synthesis in the human embryonic cornea.

Authors:  L Hyldahl; P N Schofield; W Engström
Journal:  Development       Date:  1990-07       Impact factor: 6.868
View more
  24 in total

Review 1.  The role of scaffold proteins in JNK signalling.

Authors:  W Engström; A Ward; K Moorwood
Journal:  Cell Prolif       Date:  2009-11-17       Impact factor: 6.831

2.  mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry.

Authors:  Ning Dai; Joseph Rapley; Matthew Angel; M Fatih Yanik; Michael D Blower; Joseph Avruch
Journal:  Genes Dev       Date:  2011-05-16       Impact factor: 11.361

3.  Development of targeted therapy for a broad spectrum of cancers (pancreatic cancer, ovarian cancer, glioblastoma and HCC) mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences.

Authors:  Doron Amit; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2012-08-22

4.  Kinetics and regulation of site-specific endonucleolytic cleavage of human IGF-II mRNAs.

Authors:  E L van Dijk; J S Sussenbach; P E Holthuizen
Journal:  Nucleic Acids Res       Date:  2001-09-01       Impact factor: 16.971

5.  Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Tatiana Birman; Ofer N Gofrit; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2011-04-30

6.  Immunoexpression of IGF1, IGF2, and osteopontin in craniofacial bone repair associated with autogenous grafting in rat models treated with alendronate sodium.

Authors:  Paulo Roberto Camati; Allan Fernando Giovanini; Hugo Eduardo de Miranda Peixoto; Cassiana Majewski Schuanka; Maria Cecília Giacomel; Melissa Rodrigues de Araújo; João César Zielak; Rafaela Scariot; Tatiana Miranda Deliberador
Journal:  Clin Oral Investig       Date:  2016-10-22       Impact factor: 3.573

7.  Effects of fibroblast growth factor 2 and insulin-like growth factor II on the development of parthenogenetic mouse embryos in vitro.

Authors:  L I Penkov; E S Platonov; D A New
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001 Jul-Aug       Impact factor: 2.416

8.  A maize insulin-like growth factor signals to a transduction pathway that regulates protein synthesis in maize.

Authors:  C García Flores; R Aguilar; H Reyes de la Cruz; M Albores; E Sánchez de Jiménez
Journal:  Biochem J       Date:  2001-08-15       Impact factor: 3.857

9.  Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2013-01-26

10.  IGF-II promoter methylation and ovarian cancer prognosis.

Authors:  A C Beeghly; D Katsaros; A L Wiley; I A Rigault de la Longrais; A T Prescott; H Chen; M Puopolo; T J Rutherford; H Yu
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-14       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.